FAMEWAVE

FameWave is a privately held biopharmaceutical company developing CM-24, a clinical stage monoclonal antibody targeting CEACAM1, a novel immune checkpoint. Kitov is planning initiation of a Phase I/II study in early 2020 to evaluate the safety and efficacy of CM-24 in combination with an anti PD-1 inhibitor.

#SimilarOrganizations #More

FAMEWAVE

Industry:
Biotechnology Pharmaceutical

Status:
Active


Similar Organizations

laurent-pharmaceuticals-logo

Laurent Pharmaceuticals

Laurent Pharmaceuticals is a private biopharmaceutical company developing a clinical stage, orally-active drug candidate.

oncusp-therapeutics-logo

OnCusp Therapeutics

OnCusp Therapeutics is a biopharmaceutical company turning cutting-edge research assets into innovative oncology treatments.

pharmakea-therapeutics-logo

PharmAkea Therapeutics

PharmAkea is a biopharmaceutical company developing small molecule drug candidates targeting proteins in fibroproliferative diseases.

More informations about "FameWave" on Search Engine